Preclinical data to be presented highlight sustained and normalized Factor VIII activity following single dose of P-FVIII-101 for the treatment of Hemophilia A P-FVIII-101 is a liver-directed gene ...
WALTHAM, Mass.--(BUSINESS WIRE)--BostonGene, a leading provider of AI-driven molecular and immune profiling solutions, today announced the selection of four abstracts for oral presentation, four ...
Collaborative Presentations Showcase BostonGene’s AI-Driven Innovations in Molecular and Immunoprofiling as Essential for Advancing Cancer Therapies Through Microenvironment and Immune Cell ...
PRINCETON, N.J., Nov. 13, 2025 /PRNewswire/ -- Taiho Oncology, Inc., a company developing and commercializing novel treatments for hematologic malignancies and solid tumors, announced the presentation ...
WALTHAM, Mass.--(BUSINESS WIRE)--BostonGene Corporation, a biomedical software company committed to defining optimal precision medicine-based therapies for cancer patients, today announced that seven ...
-- Median duration of response, progression free survival, and overall survival rate not reached with median follow-up after CART-ddBCMA infusion of 22 months -- -- A more recent data cut will be ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback